

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LUYE PHARMA GROUP LTD.

绿叶制药集团有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 02186)

**POLL RESULTS OF THE ANNUAL GENERAL MEETING
HELD ON 25 MAY 2023
AND
APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR**

At the annual general meeting (the “AGM”) of Luye Pharma Group Ltd. (the “**Company**”) held on 25 May 2023, a poll was demanded by the chairman of the AGM for voting on all the proposed resolutions as set out in the notice of the AGM dated 28 April 2023 (the “**AGM Notice**”).

As at the date of the AGM, the total number of issued shares of the Company was 3,761,670,643 shares of US\$0.02 each, being the total number of shares entitling the shareholders of the Company (the “**Shareholders**”) to attend and vote for or against the resolutions at the AGM. There were no restrictions on any Shareholders casting vote on any of the proposed resolutions at the AGM. No Shareholder was required to attend and vote only against the proposed resolutions at the AGM. None of the Shareholders has stated their intention in the circular of the Company dated 28 April 2023 (the “**Circular**”) to vote against or to abstain from voting on the proposed resolutions at the AGM.

The Company’s Hong Kong share registrar, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the AGM for the purpose of vote-taking.

POLL RESULTS OF AGM

The poll results in respect of the respective resolutions proposed at the AGM were as follow:

ORDINARY RESOLUTIONS		No. of Votes (%)	
		For	Against
1.	To receive and adopt the audited consolidated financial statements of the Company and the reports of the directors of the Company (the “ Directors ”) and of the auditor of the Company (the “ Auditor ”) for the year ended 31 December 2022.	1,908,424,072 (99.786563%)	4,082,000 (0.213437%)
2.	(a) To re-elect Ms. ZHU Yuan Yuan as a an executive Director;	1,902,417,784 (99.472509%)	10,088,288 (0.527491%)
	(b) To re-elect Mr. SONG Rui Lin as a non-executive Director;	1,882,850,357 (98.449379%)	29,655,715 (1.550621%)
	(c) To re-elect Professor LO Yuk Lam as an independent non-executive Director;	1,897,942,873 (99.238528%)	14,563,199 (0.761472%)
	(d) To re-elect Mr. LEUNG Man Kit as an independent non-executive Director; and	1,765,499,622 (92.313413%)	147,006,450 (7.686587%)
	(e) To authorise the board of directors of the Company (the “ Board ”) to fix the remuneration of the Directors.	1,909,427,672 (99.839038%)	3,078,400 (0.160962%)
3.	To consider and approve the appointment of Ms. XIA Lian as an independent non-executive Director.	1,912,496,072 (99.999477%)	10,000 (0.000523%)
4.	To re-appoint Ernst & Young as the Auditor to hold office until the conclusion of the next annual general meeting of the Company and to authorise the Board to fix their remuneration for the year ending 31 December 2023.	1,910,906,572 (99.916366%)	1,599,500 (0.083634%)
5.	(A) To give a general mandate to the Directors to allot, issue and deal with additional shares not exceeding 20% of the issued share capital of the Company (the “ Issue Mandate ”).	1,757,435,918 (91.891782%)	155,070,154 (8.108218%)
	(B) To give a general mandate to the Directors to repurchase shares not exceeding 10% of the issued share capital of the Company.	1,910,906,572 (99.916366%)	1,599,500 (0.083634%)
	(C) To extend the Issue Mandate by the number of shares repurchased by the Company.	1,759,982,475 (92.024935%)	152,523,597 (7.975065%)

Note: Please refer to the AGM Notice for the full text of the resolutions.

As more than 50% of the votes were cast in favour of the resolutions, all resolutions proposed at the AGM were duly passed by way of poll as ordinary resolutions by the Shareholders.

All directors of the Company (except for Mr. SONG Rui Lin and Mr. SUN Xin, who were unable to attend due to other work commitment) attended the AGM.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board is pleased to announce that, upon consideration and approval by way of an ordinary resolution at the AGM, Ms. XIA Lian (“**Ms. Xia**”) has been appointed as an independent non-executive Director with effect from the conclusion of the AGM for a term of two years.

The biographical details of Ms. Xia and her information required to be disclosed under Rule 13.51(2) of The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited were set out in Appendix II to the Circular. As at the date of this announcement, there was no change in such information.

The Board would like to welcome Ms. Xia in joining the Board.

By order of the Board
LUYE PHARMA GROUP LTD.
Liu Dian Bo
Chairman

Hong Kong, 25 May 2023

As at the date of this announcement, the executive directors of the Company are Mr. LIU Dian Bo, Mr. YANG Rong Bing, Mr. YUAN Hui Xian and Ms. ZHU Yuan Yuan; the non-executive directors of the Company are Mr. SONG Rui Lin and Mr. SUN Xin; and the independent non-executive directors of the Company are Mr. ZHANG Hua Qiao, Professor LO Yuk Lam, Mr. LEUNG Man Kit, Mr. CHOY Sze Chung Jojo and Ms. XIA Lian.